Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1566)	2/16/2006 1:52:45 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

DRRX Seems to have found support at the 4.05 level. bigcharts.marketwatch.com It presented yesterday afternoon at the BIO CEO Conference in NY. On Jan.26 it announced that it plans to expand the use for its P.O. pain relief depot, SABER (Bupivacaine) & was initiating a PII on orthopedic procedures.It has received a US IND for SABER. The stock needs to close above 5.10 in order to get off from its longer term downtrend coming from its Oct. H of 7.39 (That Oct. H was short of its Sep. H of 7.43 <g>) bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1566)	10/19/2007 9:51:27 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANPI is trying to hold the $7.50 level bigcharts.marketwatch.com Today it announced preliminary results for its 3rdQ & increased its guidance.<g> biz.yahoo.com ANPI has had increased losses in the 1st 2Qs & the revenues were also 23% lower in the 2ndQ. The stock is starting to get off the DT coming from the March 2006 H at the 16 level. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1566)	2/12/2008 1:38:23 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BSX Is up 1.77% in spite of the verdict against it in the patent infringement suit regarding its Taxus drug-eluting stent products in which the jury awarded damages of $431M. Volume remains relatively moderate at 3,838,790 which is < half its ADV & the stock is trying to get above the $13 level. bigcharts.marketwatch.com BSX believes the jury verdict is unsupported by the evidence & the law, & will try to overturn the verdict, it believes that it will prevail on appeal. The stock is trading around 1.2xBV with + CF; the insiders hold > 10% & institutions around 30%; the short ratio is up about 5% & around 4x its ADV The "analysts" have a target of $14.80 but it seems that with some good news it could easily get to the $16 level bigcharts.marketwatch.com Bernard